<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29267617</article-id><article-id pub-id-type="pmc">5731309</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Relationship between Brain Natriuretic Peptide and Recurrence of
Atrial Fibrillation after Successful Electrical Cardioversion: an Updated
Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Xiangdong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Yongqing</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">
<label>1</label> Central Hospital, Jiading District, Shangai, China.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Xiangdong Xu, Central hospital, Jiading
District, 1 Chengbei Road - Jiading District - Shanghai, China - 201800. E-mail:
<email>tyqyyyqw@163.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2017</year></pub-date><volume>32</volume><issue>6</issue><fpage>530</fpage><lpage>535</lpage><history><date date-type="received"><day>10</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>5</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To investigate the relationship between brain natriuretic peptide and
recurrence of atrial fibrillation after successful electrical
cardioversion.</p></sec><sec><title>Methods</title><p>Medline and Embase databases were used to identify publications evaluating
BNP/N-Terminal (NT)-proBNP levels in association with atrial fibrillation
recurrence after successful electrical cardioversion. Nineteen studies that
fulfilled the specified criteria of our analysis were found.</p></sec><sec><title>Results</title><p>Baseline BNP/NT-proBNP levels of the atrial fibrillation recurrence group
were significantly higher than those of the sinus rhythm maintaining group
(SMD -0.70, CI [-0.82, -0.58]).</p></sec><sec><title>Conclusion</title><p>Our analysis suggests that low BNP/NT-proBNP levels are associated with sinus
rhythm maintenance, and baseline BNP/NT-proBNP concentrations may be a
predictor of atrial fibrillation recurrence after successful electrical
cardioversion.</p></sec></abstract><kwd-group><kwd>Atrial Fibrillation</kwd><kwd>Atrial Flutter</kwd><kwd>Electric Countershock</kwd><kwd>Natriuretic Peptide, Brain</kwd></kwd-group><funding-group><award-group><funding-source>Shanghai Municipal Health and Family Planning
Commission</funding-source><award-id>ZK2015B09</award-id></award-group><funding-statement>Shanghai Municipal Health and Family Planning Commission provided
financial support for the project (ZK2015B09).</funding-statement></funding-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AF</td><td align="left" rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP</td><td align="left" rowspan="1" colspan="1">= Brain natriuretic peptide</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF</td><td align="left" rowspan="1" colspan="1">= Left ventricular ejection fraction</td></tr><tr><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">= Sinus rhythm</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is a costly disease
associated with significant morbidity and mortality. There are two modalities of
treatment for AF: rate control and rhythm control. Rhythm control is preferred in
cases in which sinus rhythm (SR) is expected to be maintained after cardioversion.
Direct-current cardioversion is frequently used to restore SR in patients with AF,
but the recurrence rate of AF after direct-current cardioversion is 50% after six
months<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. There are many
predictors of SR after cardioversion of AF, of which BNP/NT-proBNP is a commonly
described one.</p><p>Evidence from several studies supports the relationship between BNP/NT-proBNP and AF
recurrence before electrical cardioversion, but other studies have failed to find an
association. In 2011, a meta-analysis by Tang et al.<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>, which included 10 trials and 618 patients,
concluded that higher plasma BNP levels are associated with a greater risk of AF
recurrence. Since 2011, nine additional randomized controlled trials were published
with double the sample size and that contained information on the association
between BNP/NT-proBNP and AF recurrence.</p><p>Under this circumstance, this updated meta-analysis was conducted to reveal a wealth
of evidence and provide more valid information for clinical practice.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Search Strategy and Selection Criteria</title><p>This analysis was performed according to the guideline of the Meta-analysis of
Observational Studies in Epidemiology Group<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Medline and Embase databases were used to identify
relevant publications indexed between January 1980 and August 2016, using the
following key words ["natriuretic peptide" and "atrial fibrillation"] or
["atrial fibrillation" and "cardioversion"] or ["atrial fibrillation" and
"electrical cardioversion"]. We reviewed abstracts except for articles that
focused on natriuretic peptide in AF cardioversion, for which we obtained full
text. A review for the references of identified studies was conducted and
limited the language to English. The corresponding authors were contacted if
further unpublished data were needed. And a manual search was also conducted for
relevant review articles and for abstracts of the scientific sessions of the
American College of Cardiology, the American Heart Association and the European
Society of Cardiology for the past five years.</p><p>Studies were considered eligible for inclusion in our meta-analysis if they meet
the following criteria: (i) they were observational studies; (ii) they evaluated
the potential relationship between plasma BNP/NT-proBNP levels before
cardioversion and AF recurrence after successful electrical cardioversion; (iii)
they used AF recurrence rates as an index of the outcome; and (iv) they used a
follow-up period of &#x02265; 5 days. The 5-day follow-up was decided on the
basis of the 2010 European Society of Cardiology guidelines, which indicate a
late recurrence of AF that occurs more than five days after successful
electrical cardioversion<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.</p></sec><sec><title>Assessment of Study Quality</title><p>To examine biases in the studies and their effects, quality assessments according
to the following criteria were conducted: (i) whether the inclusion criteria and
the end of the event were clearly defined; (ii) whether the follow-up period was
adequate; (iii) whether all cases were followed up (<italic>i.e.</italic>,
withdrawal rate was &#x0003c;20%); (iv) whether confounding and predicting factors
were distinguished; and (v) whether there was a clear description of the
detection system used to identify the incident endpoint.</p></sec><sec><title>Data Extraction</title><p>Two reviewers independently extracted data from each study. Results were
compared, and any disagreements were resolved by consensus. The extracted data
included first author, patient characteristics (<italic>e.g.</italic>, left
ventricular ejection fraction (LVEF), AF duration, follow-up period), AF
detection methods, number of AF recurrence and SR-maintaining patients, and mean
and standard deviation (SD) of BNP/NT-proBNP concentrations in the AF recurrence
and SR-maintaining groups. If the documents provided medians and range, the
method of Hozo et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> was
used to calculate the mean and SD.</p></sec><sec><title>Statistical Analysis</title><p>Data were collected and analyzed using STATA software (version 12.0 STATA Corp.,
College Station, TX, USA). Cochrane's Q test is the most commonly used method to
evaluate heterogeneity. In our article, the result of this test is shown by
I<sup>2</sup>, because the I<sup>2</sup> statistic describes the percentage
of variation across studies that is due to heterogeneity rather than due to
chance. I<sup>2</sup> = 100% x (Q-df )/Q. I<sup>2</sup> is an intuitive and
simple expression of the inconsistency in studies' results. We considered an
I<sup>2</sup> statistic of 50% or more as indicative of a considerable level
of heterogeneity; if I<sup>2</sup> &#x0003e;50%, the random effects model was
used<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Otherwise, the
fixed effect model was used. We planned to perform sensitivity analysis and
subgroup analysis to explore the potential influence of heterogeneity.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Literature Search</title><p>Our initial literature search identified 1,064 studies (<xref ref-type="fig" rid="f1">Figure 1</xref>), of which 19 were selected in our
analysis<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>. A total of 1,373 patients
were enrolled in these studies: 657 cases were classified in the AF recurrence
group and 716 in the SR-maintaining group. Basic characteristics of the 19
studies are shown in <xref ref-type="table" rid="t1">Table 1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Meta-analysis flowchart.</p></caption><graphic xlink:href="rbccv-32-06-0530-g01"/></fig>
</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Basic characteristics of the included studies.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Study characteristics</th><th align="center" rowspan="1" colspan="1">AF duration</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">AF recurrence rate</th><th align="center" rowspan="1" colspan="1">Follow-up period</th><th align="center" rowspan="1" colspan="1">AF detection</th><th align="center" rowspan="1" colspan="1">Detection index</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lewicka et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup></td><td align="center" rowspan="1" colspan="1">preserved LVEF 55&#x000b1;5%</td><td align="center" rowspan="1" colspan="1">median 51 days</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">92%</td><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">pacemaker logs</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Andersson et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup></td><td align="center" rowspan="1" colspan="1">10% patients with heart failure</td><td align="center" rowspan="1" colspan="1">&#x0003e;7 days</td><td align="center" rowspan="1" colspan="1">199</td><td align="center" rowspan="1" colspan="1">54%</td><td align="center" rowspan="1" colspan="1">1 month</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Mukherjee et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup></td><td align="center" rowspan="1" colspan="1">preserved LVEF 56.78&#x000b1;140.6%</td><td align="center" rowspan="1" colspan="1">&#x0003c;1 year</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">44%</td><td align="center" rowspan="1" colspan="1">12&#x000b1;2 weeks</td><td align="center" rowspan="1" colspan="1">Physical, ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Govindan et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup></td><td align="center" rowspan="1" colspan="1">preserved LVEF&#x0003e;50%</td><td align="center" rowspan="1" colspan="1">&#x0003c;18 months</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">61%</td><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">Holter, ECG, physical</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Kawamura et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup></td><td align="center" rowspan="1" colspan="1">preserved LVEF 61.1&#x000b1;9.6%</td><td align="center" rowspan="1" colspan="1">37&#x000b1;26 days</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">38%</td><td align="center" rowspan="1" colspan="1">24 months</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Barassi et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup></td><td align="center" rowspan="1" colspan="1">preserved LVEF 58.7&#x000b1;6%</td><td align="center" rowspan="1" colspan="1">3 months</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">33%</td><td align="center" rowspan="1" colspan="1">3 weeks</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Falcone et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NYHA I or II</td><td align="center" rowspan="1" colspan="1">93&#x000b1;65 days</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">28%</td><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">Holter, ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Wozakowska-Kaplon et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NYHA I, LVEF 58.1&#x000b1;6.4 %</td><td align="center" rowspan="1" colspan="1">&#x0003e;48 hours, &#x0003c;12 months</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">39%</td><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">ECG, Holter</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Kallergis et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup></td><td align="center" rowspan="1" colspan="1">LVEF 57.1&#x000b1; 8.5%</td><td align="center" rowspan="1" colspan="1">&#x0003e;3 months</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">23%</td><td align="center" rowspan="1" colspan="1">1 month</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Ari et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup></td><td align="center" rowspan="1" colspan="1">preserved LVEF 55.5&#x000b1;2.98%</td><td align="center" rowspan="1" colspan="1">23.2&#x000b1;6.5 months</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">34.5%</td><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Mollmann et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup></td><td align="center" rowspan="1" colspan="1">LVEF &#x0003e;45%</td><td align="center" rowspan="1" colspan="1">181.5&#x000b1;327days</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">36%</td><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">Holter, ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Lombardi et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup></td><td align="center" rowspan="1" colspan="1">LVEF &#x0003e;45%</td><td align="center" rowspan="1" colspan="1">1 month-1 year</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">34%</td><td align="center" rowspan="1" colspan="1">3 weeks</td><td align="center" rowspan="1" colspan="1">Holter, ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Tveit et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NHYA I</td><td align="center" rowspan="1" colspan="1">median 10.5 weeks</td><td align="center" rowspan="1" colspan="1">129</td><td align="center" rowspan="1" colspan="1">69%</td><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Buob et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup></td><td align="center" rowspan="1" colspan="1">LVEF 57&#x000b1;11%</td><td align="center" rowspan="1" colspan="1">90&#x000b1;75 days</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">44%</td><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">Physical, ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Shin et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">normal LVEF</td><td align="center" rowspan="1" colspan="1">10.9&#x000b1;8.3 weeks</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">29.4%</td><td align="center" rowspan="1" colspan="1">11 days</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">NT-proBNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Lellouche et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NYHA I or II</td><td align="center" rowspan="1" colspan="1">3.7 months</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">45%</td><td align="center" rowspan="1" colspan="1">1 year</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Mabuchi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NYHA II or III</td><td align="center" rowspan="1" colspan="1">mean 5.8 months</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">45%</td><td align="center" rowspan="1" colspan="1">553 days</td><td align="center" rowspan="1" colspan="1">Physical, ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Beck-da-Silva et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NYHA I or II, preserved LVEF</td><td align="center" rowspan="1" colspan="1">6 months</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">36%</td><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr><tr><td align="left" rowspan="1" colspan="1">Watanabe et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup></td><td align="center" rowspan="1" colspan="1">NYHA I -III, LVEF 59&#x000b1;10%</td><td align="center" rowspan="1" colspan="1">(1-350) days</td><td align="center" rowspan="1" colspan="1">84</td><td align="center" rowspan="1" colspan="1">76%</td><td align="center" rowspan="1" colspan="1">12 months</td><td align="center" rowspan="1" colspan="1">Holter, ECG</td><td align="center" rowspan="1" colspan="1">BNP</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AF=atrial fibrillation; BNP=brain natriuretic peptide;
ECG=electrocardiogram; LVEF=left ventricular ejection fraction;
NYHA=New York Heart Association</p></fn></table-wrap-foot></table-wrap><p>Findings from the meta-analysis related to the relationship between plasma
BNP/NT-proBNP level and AF recurrence after successful electrical cardioversion
in patients with AF are shown in <xref ref-type="fig" rid="f2">Figure 2</xref>.
When data were pooled across studies, the baseline BNP/NT-proBNP levels in the
AF recurrence group were significantly higher than those in the SR-maintaining
group (SMD -0.70, CI [-0.82, -0.58]).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig 2</label><caption><p>BNP/NT-proBNP levels and AF recurrence: an updated meta-analysis.</p></caption><graphic xlink:href="rbccv-32-06-0530-g02"/></fig>
</p><p>Evidence of significant heterogeneity was observed (<italic>P</italic>&#x0003c;0.0001;
I<sup>2</sup>=92.8%). We analyzed the heterogeneity using the random effects
model. To explore potential reasons for heterogeneity, we conducted a subgroup
analysis to investigate the effect of follow-up duration on BNP/NT-proBNP levels
between the SR and AF groups, because the duration of the follow-up period was a
major difference in the included studies. This subgroup analysis showed in the
long-term follow-up subgroup (defined as followup &#x0003e;1 month) (SMD -0.63, CI
[-0.78, -0.47]) and the short-term follow-up subgroup (defined as follow-up of
&#x02264; 1 month (SMD -0.82, CI [-1.02, -0.62]), baseline BNP/NT-proBNP levels
in the AF recurrence group were significantly higher than BNP/NT-proBNP levels
in the SR-maintaining group (<xref ref-type="fig" rid="f3">Figure 3</xref>).
This indicated than BNP/NT-proBNP concentrations in the AF recurrence group were
significantly higher than those in the SR-maintaining group.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>BNP/NT-proBNP levels and AF recurrence: subgroup analysis.</p></caption><graphic xlink:href="rbccv-32-06-0530-g03"/></fig>
</p><p>When the study with the shortest follow-up<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> was discarded, the sensitivity analysis produced
results similar to those obtained when this study was included (SMD -0.69, CI
[-0.81, -0.57]). The heterogeneity was observed in our analysis, which may be
attributed to differences in patient characteristics, such as etiology, AF
duration, age, and heart function. Possible language and publication biases may
also be considered. Distribution of data points on a funnel plot (Begg test)
indicated that bias were possibly related to language and publication bias
(<xref ref-type="fig" rid="f4">Figure 4</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Begg's funnel plot.</p></caption><graphic xlink:href="rbccv-32-06-0530-g04"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our meta-analysis aimed to further explore the relationship between BNP/NT-proBNP
levels before successful electrical cardioversion in patients who maintained SR and
who had AF recurrence during the follow-up period. The result of our analysis showed
that patients with lower BNP/NT-proBNP concentrations were more likely to remain in
SR after successful electrical cardioversion. This analysis was conducted in 2011,
when 10 studies were included in our analysis. Our present analysis contains nine
additional studies, including studies with negative results and twice the number of
patients. A previous meta-analysis by Zografos et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> was conducted. In contrast to their
meta-analysis, we pooled the BNP/NT-proBNP results. Moreover, the studies involving
both electrical cardioversion and pharmacologic cardioversion were excluded.</p><p>B-type natriuretic peptide, a neurohormone, is synthesized as a prohormone in the
heart in response to increased myocardial wall stress from volume or pressure
loading and other factors. The peptide proBNP is cleaved into BNP and the
biologically inactive fragment NT-proBNP. BNP is secreted primarily by ventricular
myocytes. In the patients in our analysis, which mainly have preserved ejection
fraction, high BNP/NT-proBNP level may have occurred for a different reason. In
patients with AF, there is evidence that BNP is secreted by the atrium. Tuinenburg
et al.<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup> studied atrial BNP gene
expression in patients with paroxysmal and persistent AF and found that the atrium
was the major site of BNP gene expression. Silvet et al.<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup> found that the increase in BNP levels after
atrial stretching and volume overload was closely related to chronic AF. In
addition, pathologic changes such as the enlargement and fibrosis of the atrium may
also cause increased BNP<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>. BNP
levels may also reflect a higher degree of systematic inflammation, which is
consistently associated with AF<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. The question of whether BNP/NT-proBNP can be used as an
effective indicator in the proactive prevention of AF or its recurrence or in the
likelihood of success of cardioversion treatment has, therefore, attracted wide
attention.</p><p>The present updated meta-analysis of 19 AF-related publications<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup> showed that after successful electrical cardioversion, AF was
more likely to recur in patients with high, rather than low, plasma BNP/NT-proBNP
concentrations. This indicates that plasma BNP/NT-proBNP level is a predictor of AF
recurrence. Our subgroup analysis achieved the same result, regardless of the long-
and short-term follow-up period, which indicated that the baseline BNP/NT-proBNP
concentrations may be a predictor of AF recurrence after successful electrical
cardioversion. Distribution of data points on the funnel plot graph after
application of the random effects model indicated possible language and publication
biases.</p><p>As a biomarker indicator, plasma BNP/NT-proBNP level has the advantages of cost-
effectiveness, convenience, and a high degree of reliability<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. The measurement of plasma
BNP/NT-proBNP levels may help predict the risk of AF recurrence, thus helping the
initial selection of suitable patients for AF treatment.</p><p>Our analysis suggests that low BNP/NT-proBNP levels are associated with SR
maintenance, which is consistent with our previous finding even after including nine
additional studies and doubling the number of patients. Even though using
BNP/NT-proBNP levels could not guide electrical cardioversion by current evidence,
our work's purpose is to suggest that BNP/NT-proBNP levels may help predict the risk
of AF recurrence, thus helping the initial selection of suitable patients for
electrical cardioversion; therefore, further research is needed to explore such a
cutoff of BNP/NT-proBNP value to select the right patients for electrical
cardioversion.</p><sec><title>Study Limitations</title><p>A limitation of this study is the significant heterogeneity, which probably
reflects several differences between the included studies, such as patient
characteristics. Nevertheless, we failed to observe a significant difference
between studies with short- long-term follow-up. Another potential factor
contributing to the observed heterogeneity is the difference in patient
characteristics, such as etiology and ejection fraction. We included patients
with AF with varying etiology; details of the etiology were not always
available, even though the majority of studies included patients with preserved
LV systolic function, and details on diastolic or left atrial function were not
always available. Differences in these variables may account for the observed
between-study differences as well as the significant in-study variation, which
is evident in the wide SD of BNP or NT-proBNP levels observed in many
studies.</p><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026;
responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">XX</td><td align="left" rowspan="1" colspan="1">Conception, acquisition, analysis, interpretation
of data, work review; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">YT</td><td align="left" rowspan="1" colspan="1">Conception, acquisition, analysis, interpretation
of data, work review; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="other"><p>This study was carried out at Jiading District Central Hospital, Shanghai,
China.</p></fn><fn fn-type="financial-disclosure"><p>Financial Support: Shanghai Municipal Health and Family Planning Commission
provided financial support for the project (ZK2015B09).</p></fn></fn-group><ack><title>ACKNOWLEDGEMENTS</title><p>Sincere appreciations are expressed to the reviewers for their comments and
suggestions on this paper.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimold</surname><given-names>SC</given-names></name><name><surname>Cantillon</surname><given-names>CO</given-names></name><name><surname>Friedman</surname><given-names>PL</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name></person-group><article-title>Propafenone versus sotalol for suppression of recurrent
symptomatic atrial fibrillation</article-title><source>Am J Cardiol</source><year>1993</year><volume>71</volume><issue>7</issue><fpage>558</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">8438741</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name></person-group><article-title>Relationship between brain natriuretic peptide and recurrence of
atrial fibrillation after successful electrical cardioversion: a
meta-analysis</article-title><source>J Int Med Res</source><year>2011</year><volume>39</volume><issue>5</issue><fpage>1618</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">22117962</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroup</surname><given-names>DF</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Morton</surname><given-names>SC</given-names></name><name><surname>Olkin</surname><given-names>I</given-names></name><name><surname>Williamson</surname><given-names>GD</given-names></name><name><surname>Rennie</surname><given-names>D</given-names></name><etal/></person-group><article-title>Meta-analysis of observational studies in epidemiology: a
proposal for reporting. Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) group</article-title><source>JAMA</source><year>2000</year><volume>283</volume><issue>15</issue><fpage>2008</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">10789670</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Schotten</surname><given-names>U</given-names></name><name><surname>Savelieva</surname><given-names>I</given-names></name><name><surname>Ernst</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guidelines for the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation of the European Society of
Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>19</issue><fpage>2369</fpage><lpage>2429</lpage><pub-id pub-id-type="pmid">20802247</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hozo</surname><given-names>SP</given-names></name><name><surname>Djulbegovic</surname><given-names>B</given-names></name><name><surname>Hozo</surname><given-names>I</given-names></name></person-group><article-title>Estimating the mean and variance from the median, range, and the
size of a sample</article-title><source>BMC Med Res Methodol</source><year>2005</year><volume>5</volume><fpage>13</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15840177</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Quantifying heterogeneity in a meta-analysis</article-title><source>Stat Med</source><year>2002</year><volume>21</volume><issue>11</issue><fpage>1539</fpage><lpage>1558</lpage><pub-id pub-id-type="pmid">12111919</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewicka</surname><given-names>E</given-names></name><name><surname>Dudzi&#x00144;ska-Gehrmann</surname><given-names>J</given-names></name><name><surname>D&#x00105;browska-Kugacka</surname><given-names>A</given-names></name><name><surname>Zago&#x0017c;d&#x0017c;on</surname><given-names>P</given-names></name><name><surname>Stepnowska</surname><given-names>E</given-names></name><name><surname>Li&#x0017c;ewska</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plasma biomarkers as predictors of recurrence of atrial
fibrillation</article-title><source>Pol Arch Med Wewn</source><year>2015</year><volume>125</volume><issue>6</issue><fpage>424</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">26038944</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Rosenqvist</surname><given-names>M</given-names></name><name><surname>Tornvall</surname><given-names>P</given-names></name><name><surname>Boman</surname><given-names>K</given-names></name></person-group><article-title>NT-proBNP predicts maintenance of sinus rhythm after electrical
cardioversion</article-title><source>Thromb Res</source><year>2015</year><volume>135</volume><issue>2</issue><fpage>289</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">25481046</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>R</given-names></name><name><surname>Akar</surname><given-names>JG</given-names></name><name><surname>Wharton</surname><given-names>JM</given-names></name><name><surname>Adams</surname><given-names>DK</given-names></name><name><surname>McClure</surname><given-names>CD</given-names></name><name><surname>Stroud</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Plasma profiles of matrix metalloproteinases and tissue
inhibitors of the metalloproteinases predict recurrence of atrial
fibrillation following cardioversion</article-title><source>J Cardiovasc Transl Res</source><year>2013</year><volume>6</volume><issue>4</issue><fpage>528</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">23722357</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindan</surname><given-names>M</given-names></name><name><surname>Borgulya</surname><given-names>G</given-names></name><name><surname>Kiotsekoglou</surname><given-names>A</given-names></name><name><surname>Saha</surname><given-names>SK</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name></person-group><article-title>Prognostic value of left atrial expansion index and
exercise-induced change in atrial natriuretic peptide as long-term
predictors of atrial fibrillation recurrence</article-title><source>Europace</source><year>2012</year><volume>14</volume><issue>9</issue><fpage>1302</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">22654096</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>M</given-names></name><name><surname>Munetsugu</surname><given-names>Y</given-names></name><name><surname>Kawasaki</surname><given-names>S</given-names></name><name><surname>Onishi</surname><given-names>K</given-names></name><name><surname>Onuma</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Type III procollagen-N-peptide as a predictor of persistent
atrial fibrillation recurrence after cardioversion</article-title><source>Europace</source><year>2012</year><volume>14</volume><issue>12</issue><fpage>1719</fpage><lpage>1725</lpage><pub-id pub-id-type="pmid">22622138</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barassi</surname><given-names>A</given-names></name><name><surname>Pezzilli</surname><given-names>R</given-names></name><name><surname>Morselli-Labate</surname><given-names>AM</given-names></name><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>Belletti</surname><given-names>S</given-names></name><name><surname>Dogliotti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Serum amyloid and C-reactive protein independently predict the
recurrences of atrial fibrillation after cardioversion in patients with
preserved left ventricular function</article-title><source>Can J Cardiol</source><year>2012</year><volume>28</volume><issue>5</issue><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">22552174</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>C</given-names></name><name><surname>Buzzi</surname><given-names>MP</given-names></name><name><surname>D'Angelo</surname><given-names>A</given-names></name><name><surname>Schirinzi</surname><given-names>S</given-names></name><name><surname>Falcone</surname><given-names>R</given-names></name><name><surname>Rordorf</surname><given-names>R</given-names></name><etal/></person-group><article-title>Apelin plasma levels predict arrhythmia recurrence in patients
with persistent atrial fibrillation</article-title><source>Int J Immunopathol Pharmacol</source><year>2010</year><volume>23</volume><issue>3</issue><fpage>917</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">20943064</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wozakowska-Kap&#x00142;on</surname><given-names>B</given-names></name><name><surname>Bartkowiak</surname><given-names>R</given-names></name><name><surname>Grabowska</surname><given-names>U</given-names></name><name><surname>Janiszewska</surname><given-names>G</given-names></name></person-group><article-title>B-type natriuretic peptide level after sinus rhythm restoration
in patients with persistent atrial fibrillation - clinical
significance</article-title><source>Kardiol Pol</source><year>2010</year><volume>68</volume><issue>7</issue><fpage>781</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">20648436</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallergis</surname><given-names>EM</given-names></name><name><surname>Manios</surname><given-names>EG</given-names></name><name><surname>Kanoupakis</surname><given-names>EM</given-names></name><name><surname>Mavrakis</surname><given-names>HE</given-names></name><name><surname>Goudis</surname><given-names>CA</given-names></name><name><surname>Maliaraki</surname><given-names>NE</given-names></name><etal/></person-group><article-title>Effect of sinus rhythm restoration after electrical cardioversion
on apelin and brain natriuretic peptide prohormone levels in patients with
persistent atrial fibrillation</article-title><source>Am J Cardiol</source><year>2010</year><volume>105</volume><issue>1</issue><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">20102897</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ari</surname><given-names>H</given-names></name><name><surname>Binici</surname><given-names>S</given-names></name><name><surname>Ari</surname><given-names>S</given-names></name><name><surname>Akkaya</surname><given-names>M</given-names></name><name><surname>Koca</surname><given-names>V</given-names></name><name><surname>Bozat</surname><given-names>T</given-names></name><etal/></person-group><article-title>The predictive value of plasma brain natriuretic peptide for the
recurrence of atrial fibrillation six months after external
cardioversion</article-title><source>Turk Kardiyol Dern Ars</source><year>2008</year><volume>36</volume><issue>7</issue><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">19155659</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f6;llmann</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Els&#x000e4;sser</surname><given-names>A</given-names></name><name><surname>Nef</surname><given-names>H</given-names></name><name><surname>Dill</surname><given-names>T</given-names></name><name><surname>Rixe</surname><given-names>J</given-names></name><etal/></person-group><article-title>NT-ProBNP predicts rhythm stability after cardioversion of lone
atrial fibrillation</article-title><source>Circ J</source><year>2008</year><volume>72</volume><issue>6</issue><fpage>921</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">18503217</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>F</given-names></name><name><surname>Tundo</surname><given-names>F</given-names></name><name><surname>Belletti</surname><given-names>S</given-names></name><name><surname>Mantero</surname><given-names>A</given-names></name><name><surname>Melzi D'eril</surname><given-names>GV</given-names></name></person-group><article-title>C-reactive protein but not atrial dysfunction predicts
recurrences of atrial fibrillation after cardioversion in patients with
preserved left ventricular function</article-title><source>J Cardiovasc Med (Hagerstown)</source><year>2008</year><volume>9</volume><issue>6</issue><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">18475126</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tveit</surname><given-names>A</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><name><surname>Grundvold</surname><given-names>I</given-names></name><name><surname>Abdelnoor</surname><given-names>M</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name></person-group><article-title>Candesartan, NT-proBNP and recurrence of atrial fibrillation
after electrical cardioversion</article-title><source>Int J Cardiol</source><year>2009</year><volume>131</volume><issue>2</issue><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">18201783</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buob</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><name><surname>Siaplaouras</surname><given-names>S</given-names></name><name><surname>Neuberger</surname><given-names>HR</given-names></name><name><surname>Mewis</surname><given-names>C</given-names></name></person-group><article-title>Discordant regulation of CRP and NT-proBNP plasma levels after
electrical cardioversion of persistent atrial fibrillation</article-title><source>Pacing Clin Electrophysiol</source><year>2006</year><volume>29</volume><issue>6</issue><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">16784419</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>DI</given-names></name><name><surname>Jaekel</surname><given-names>K</given-names></name><name><surname>Schley</surname><given-names>P</given-names></name><name><surname>Sause</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Fueth</surname><given-names>R</given-names></name><etal/></person-group><article-title>Plasma levels of NT-pro-BNP in patients with atrial fibrillation
before and after electrical cardioversion</article-title><source>Z Kardiol</source><year>2005</year><volume>94</volume><issue>12</issue><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">16382379</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lellouche</surname><given-names>N</given-names></name><name><surname>Berthier</surname><given-names>R</given-names></name><name><surname>Mekontso-Dessap</surname><given-names>A</given-names></name><name><surname>Braconnier</surname><given-names>F</given-names></name><name><surname>Monin</surname><given-names>JL</given-names></name><name><surname>Duval</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Usefulness of plasma B-type natriuretic peptide in predicting
recurrence of atrial fibrillation one year after external
cardioversion</article-title><source>Am J Cardiol</source><year>2005</year><volume>95</volume><issue>11</issue><fpage>1380</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">15904651</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mabuchi</surname><given-names>N</given-names></name><name><surname>Tsutamoto</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name></person-group><article-title>Plasma cardiac natriuretic peptides as biochemical markers of
recurrence of atrial fibrillation in patients with mild congestive heart
failure</article-title><source>Jpn Circ J</source><year>2000</year><volume>64</volume><issue>10</issue><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">11059617</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck-da-Silva</surname><given-names>L</given-names></name><name><surname>Bold</surname><given-names>A</given-names></name><name><surname>Fraser</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Haddad</surname><given-names>H</given-names></name></person-group><article-title>Brain natriuretic peptide predicts successful cardioversion in
patients with atrial fibrillation and maintenance of sinus
rhythm</article-title><source>Can J Cardiol</source><year>2004</year><volume>20</volume><issue>12</issue><fpage>1245</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">15494777</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>E</given-names></name><name><surname>Arakawa</surname><given-names>T</given-names></name><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>I</given-names></name><name><surname>Hishida</surname><given-names>H</given-names></name></person-group><article-title>High-sensitivity C-reactive protein is predictive of successful
cardioversion for atrial fibrillation and maintenance of sinus rhythm after
conversion</article-title><source>Int J Cardiol</source><year>2006</year><volume>108</volume><issue>3</issue><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">15964643</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zografos</surname><given-names>T</given-names></name><name><surname>Maniotis</surname><given-names>C</given-names></name><name><surname>Katsivas</surname><given-names>A</given-names></name><name><surname>Katritsis</surname><given-names>D</given-names></name></person-group><article-title>Relationship between brain natriuretic peptides and recurrence of
atrial fibrillation after successful direct current cardioversion: a
meta-analysis</article-title><source>Pacing Clin Electrophysiol</source><year>2014</year><volume>37</volume><issue>11</issue><fpage>1530</fpage><lpage>1537</lpage><pub-id pub-id-type="pmid">25113607</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuinenburg</surname><given-names>AE</given-names></name><name><surname>Brundel</surname><given-names>BJ</given-names></name><name><surname>Van Gelder</surname><given-names>IC</given-names></name><name><surname>Henning</surname><given-names>RH</given-names></name><name><surname>Van Den Berg</surname><given-names>MP</given-names></name><name><surname>Driessen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gene expression of the natriuretic peptide system in atrial
tissue of patients with paroxysmal and persistent atrial
fibrillation</article-title><source>J Cardiovasc Electrophysiol</source><year>1999</year><volume>10</volume><issue>6</issue><fpage>827</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">10376920</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvet</surname><given-names>H</given-names></name><name><surname>Young-Xu</surname><given-names>Y</given-names></name><name><surname>Walleigh</surname><given-names>D</given-names></name><name><surname>Ravid</surname><given-names>S</given-names></name></person-group><article-title>Brain natriuretic peptide is elevated in outpatients with atrial
fibrillation</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><issue>9</issue><fpage>1124</fpage><lpage>1127</lpage><pub-id pub-id-type="pmid">14583372</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Nakahara</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Sunamori</surname><given-names>M</given-names></name></person-group><article-title>Decreased plasma brain natriuretic peptide levels after a
successful maze procedure</article-title><source>J Heart Valve Dis</source><year>2003</year><volume>12</volume><issue>3</issue><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">12803326</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Apostolakis</surname><given-names>S</given-names></name></person-group><article-title>Inflammation in atrial fibrillation</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>60</volume><issue>22</issue><fpage>2263</fpage><lpage>2270</lpage><pub-id pub-id-type="pmid">23194937</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moe</surname><given-names>GW</given-names></name></person-group><article-title>B-type natriuretic peptide in heart failure</article-title><source>Curr Opin Cardiol</source><year>2006</year><volume>21</volume><issue>3</issue><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">16601459</pub-id></element-citation></ref></ref-list></back></article>